CaroSpir, a Liquid Form of Spironolactone, Now Available in Unit Dose Cups
The new packaging allows for ease of administration and convenience.
CHF and Arrhythmias
FDA: Risk of LAAO Implant-Related Adverse Events May Be Higher for Women
The analysis included 49,357 patients undergoing LAAO procedures with the Watchman Left Atrial Appendage Closure device.
Empagliflozin Gets Breakthrough Tx Status for Heart Failure With Preserved Ejection Fraction
The designation is based on findings from the phase 3 EMPEROR-Preserved trial.
Empagliflozin Benefits Patients With Heart Failure and Preserved Ejection Fraction
The phase 3 EMPEROR-Preserved trial assessed empagliflozin in 5988 adults with heart failure with preserved ejection fraction, with and without diabetes.
Amplatzer Amulet Approved to Reduce Thromboembolic Risk in Atrial Fibrillation
The Amulet device is designed for complete immediate closure of the left atrial appendage using dual-seal technology.
Sodium Bicarbonate Injection Recalled Due to Microbial Contamination
According to the Company, intravenous administration of the affected product could lead to “site specific infections as well as serious systemic infections which may be life-threatening.”
Coffee Consumption and Arrhythmia Risk: What’s the Link?
Each additional cup of habitual coffee consumed reduced the risk of incident arrhythmia by 3%.
Heart Failure With Mildly Reduced Ejection Fraction: Treatment Options Explored
Despite an increasing emphasis on HFmrEF over the past several years, there is a lack of authoritative guidance surrounding therapeutic approaches for these patients.
Empagliflozin Cuts Risk of Hospitalization, Death in HFpEF Patients
The phase 3 EMPEROR-Preserved trial included 5988 adult patients with heart failure with preserved ejection fraction, with and without diabetes.
New-Onset SVT Following Colonoscopy Bowel Prep Explored in Case Series
A significant percentage of affected patients were observed to have dilated atria and left ventricular hypertrophy.
- Loading...
Loading...
Loading... 
Loading...